Regulatory Snapshot (2025) Regulation around compounded GLP-1 therapy centers on two practical points: ingredient identity and shortage context
The triple receptor mechanism of retatrutide, particularly the glucagon receptor component, contributes to higher GI side effect rates overall
Heres the recommended dose escalation timeline: Weeks 14: 0.25 mg Weeks 58: 0.5 mg Weeks 912: 1 mg Weeks 1316: 1.7 mg Weeks 17 and on: Stay at 1.7 mg or increase to 2.4 mg Contrave vs
Approved uses and off-label benefits Ozempic is U.S
50 Grattan analysis of Department of Health, Disability, and Ageing (2026c), Department of Health, Disability, and Ageing (2025d), and Department of Health, Disability, and Ageing (2024e)
Perfect 5-Star Ratings Across All Locations Verified patient reviews and real outcomes 75+ Years of Combined Injector Experience All treatments performed by licensed nurse injectors